共 100 条
- [11] Bang Y-J(2008)HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol 19 1523-1529
- [12] Van Cutsem E(2008)Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 797-805
- [13] Feyereislova A(2012)Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer Clin Cancer Res 18 5992-6000
- [14] Chung HC(2019)Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) Gastric Cancer 22 527-535
- [15] Shen L(2018)Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604) Eur J Cancer 105 41-49
- [16] Sawaki A(2018)Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy BMC Cancer 18 1116-1754
- [17] Yoshida K(2020)Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy Surg Case Rep 6 219-979
- [18] Yamaguchi K(2021)Current status of conversion surgery for stage IV gastric cancer Surg Today 51 1736-2403
- [19] Okumura N(1996)Recurrences and related characteristics of gastric cancer Br J Cancer 74 975-39
- [20] Tanahashi T(2004)Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22 2395-undefined